Alexandra Mcwilliams

Recommended Articles

• What This New Therapeutic Drug Trial Means for Cystic Fibrosis

  If you have cystic fibrosis, chances are that at some point you have had difficulty breathing due to mucus build-up in your lungs. That thick mucus can make it more than just hard to breathe, as it can cause inflammation and increase your chance of injury. Clear airways may be just around the corner...

• Zinc’s Role in Multiple Sclerosis Development

  Past research has shown that it is a pathological disruption of zinc homeostasis that causes multiple sclerosis-induced motor deficits and spinal cord white matter damage. It is known that an abnormal vesicular release of zinc and accumulation of intracellular zinc may help to mediate several of the...

• Tips to Overcome Procrastination for Each Type of Procrastinator

  Ever wondered how to overcome procrastination? Well, you have landed on the right page. This article focuses on how to beat procrastination. Each of us procrastinates for different reasons, and we all do it sometimes at least at one stage of our lives. There are six styles of procrastinators...

• Is Physical Therapy Meant for Long-term Use?

  Physical therapy is a form of treatment you might need when health disorders make it difficult for you to move around and perform daily tasks. It facilitates better movement and may alleviate pain. It also plays a significant role in improving or restoring your physical functioning as well as your...

• Mandy Moore Determines Whether or Not She Has Celiac Disease

  Celiac disease is becoming more popular because it has significantly increased its rate of affected people with the passage of time. People becoming more aware of the condition and how it affects the lives of people who are gluten intolerant have led big companies and franchises, such as McDonald's,...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...